To investigate whether oral contraceptive (OC) use and postmenopausal hormones (PMH) are associated with an increased risk of developing asynchronous bilateral breast cancer among women diagnosed with breast cancer younger than 55 years.
INTRODUCTION
Many premenopausal women diagnosed with breast cancer will either maintain regular menstrual cycles or regain ovarian function after treatment. A personal history of breast cancer is currently a noted contraindication for the use of many oral contraceptives (OCs). 1 At least four studies 2-5 have found no evidence of an increased risk of contralateral breast cancer among women who used OCs. The Women's Contraceptive and Reproductive Experiences (CARE) study reported no association of OC use with risk of first breast cancer 6 ; whereas the Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC) found a modest increased risk associated with recent OC use. 7 Women with breast cancer who undergo therapies beyond surgical intervention, including chemotherapy and hormonal-based therapy, often experience reduced estrogen levels. Postmenopausal hormone therapy (PMH) can be used to relieve menopausal symptoms, but has been associated with an increased risk of first breast cancer, especially combination estrogen-progestin therapy (EPT). [8] [9] [10] [11] Current guidelines for healthy women recommend avoiding combination PMH for any reason other than to relieve severe menopausal symptoms uncontrolled by other treatments. 12 For women with a history of breast cancer, PMH is contraindicated. Two randomized clinical trials investigated the use of PMH in breast cancer survivors, and although the HABITS (Hormonal Replacement
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Therapy After Breast Cancer-Is It Safe?) study showed a significant increased risk of recurrence and was terminated early, 13 a trial in Sweden found no association.
14 Several observational studies have also shown no increased risk of tumor recurrence or increased mortality associated with PMH use among breast cancer survivors. [15] [16] [17] In addition, two observational studies examined the relationship between PMH and risk of contralateral breast cancer 2, 4 ; neither demonstrated a significant association.
Women with a personal history of breast cancer may consider using OCs for contraception and PMH for relief of menopausal symptoms 18 because they lack other effective alternatives; therefore, further study is needed. In this population-based case-control study, we examine the impact of OC and PMH use before and after a diagnosis of breast cancer on risk of a second cancer in the contralateral breast.
PATIENTS AND METHODS

Study Population
The WECARE (Women's Environmental Cancer and Radiation Epidemiology) study is a multicenter, population-based case-control study that recruited women with asynchronous bilateral breast cancer (cases) and women with unilateral breast cancer (controls).
19 All participants were identified from four population-based tumor registries in the United States (covering Iowa, Orange/San Diego and Los Angeles counties in California, and three counties surrounding Seattle, Washington) and one covering Denmark.
Women were eligible to be cases if they (1) were diagnosed between January 1, 1985, and December 31, 2001 , with an invasive breast cancer that did not spread beyond the regional lymph nodes at diagnosis and a second in situ or invasive breast cancer diagnosed in the contralateral breast at least 1 year after the first breast cancer diagnosis (reference date) (2); resided in the same study reporting area for both diagnoses (3); had no previous or intervening cancer diagnosis except squamous or basal cell skin cancer or cervical carcinoma in situ (4); were alive at the time of contact and able to provide informed consent to complete the interview and blood draw; and (5) were younger than 55 years at the time of the first breast cancer diagnosis.
Two controls were individually matched to each case on year of birth, year of diagnosis, registry region at reference date, and race, and were countermatched on registry-reported radiation exposure. Counter-matching on radiation therapy was employed for statistical efficiency purposes related to the study's primary goal of assessing genetic factors underlying the effects of radiation on breast cancer risk and is described in detail elsewhere.
19 All controls met the following eligibility criteria: (1) diagnosed since January 1, 1985 , with invasive breast cancer that did not spread beyond the regional lymph nodes at diagnosis, while residing in one of the study reporting areas; (2) no diagnosis of any other cancer (except squamous or basal cell skin carcinoma or in situ cervical cancer) before their breast cancer diagnosis or at the reference date (defined as the date of first diagnosis plus the elapsed time between their matched case's two diagnoses); (3) alive at time of contact and able toprovide informed consent to complete the interview and blood draw; and (4) no prophylactic mastectomy of the contralateral breast before or within the interval from first diagnosis to reference date.
We identified 998 cases and 2,112 controls who were eligible for inclusion in this study. Interviews and blood draws were completed with 708 cases and 1,399 controls. Reasons for nonparticipation included physician refusal (0.5% cases, 1% controls), patient refusal of interview (27% cases, 31% controls), and patient blood draw refusal (3% cases, 3% controls).
We constructed 694 triplets where, per the counter-matched design, two members of each triplet received radiation treatment for their first breast cancer, according to cancer registry records. Among 11 case-control pairs, eight sets were discordant on radiation exposure, and three were concordant on exposure. We were unable to match controls to three cases, so they were excluded.
Data Collection
All participants were interviewed by telephone using a structured questionnaire. Questions focused on events occurring before the diagnosis of the first primary as well as during the at-risk period (after the first diagnosis but before the date of the second diagnosis for the case or the equivalent [reference] date for controls). Data were collected on personal demographics, medical history, family history, reproductive history, menopausal status, body size, smoking status, alcohol intake, and OC and PMH use.
Medical records, pathology reports, and hospital charts, in addition to self-reported data, were used to collect detailed treatment information (chemotherapy, hormonal therapy, radiation therapy). Information on tumor characteristics (including location in the breast, stage at diagnosis, estrogenreceptor [ER] and progesterone-receptor [PR] status, and histology) was collected from medical records and cancer registries for both the first and second primaries. For ER and PR, we used data from medical records if available. Agreement between medical and registry records was high.
The study protocol was approved by the institutional review boards at each study site in the United States and by the ethical committee system in Denmark.
Statistical Methods
To investigate the individual and joint effects of OC and PMH use on the risk of asynchronous bilateral breast cancer, we used conditional logistic regression analysis with inclusion of a log weight covariate in the model where the coefficient is fixed at one (ie, an offset). These computed weights account for the sampling probability of counter-matching, 20 and are based on the proportion of women treated with radiation for first breast cancer within the sampled risk set for each case.
In the multivariable analyses, we included known breast cancer risk factors. to determine the relationship between age at first and last use of OCs or PMH, we restricted the analysis to women who had reached the age of the last use category. Adjusted linear trend test P values were obtained by including in the multivariable models variables that assigned ordinal values to the different categories. Analyses were stratified on time since first breast cancer diagnosis (Ͻ 5 v Ն 5 years), age at first breast cancer (Ͻ 45 v Ն 45 years), body mass index (BMI; Ͻ 25 v Ն 25 kg/m 2 ), hormone-receptor status (ERϩ v ERϪ and PRϩ v PRϪ) and menopausal status (pre v post) by inclusion of product terms in the logistic models. to account for missing information, a missing indicator variable was included in the conditional logistic regression models. 21 All statistical tests were two sided. SAS release 9.1 (SAS Institute, Cary, NC) was used for all analyses.
RESULTS
Patient Characteristics
Asynchronous bilateral breast cancer cases and unilateral breast cancer controls were well matched on age, diagnosis year, registry region, and race, and counter-matched on radiation treatment (Table  1) . Cases and controls did not differ on age at reference date or time at risk. Cases were more likely to have a family history of breast cancer, an age of menarche younger than 13 years, and fewer children than controls. Cases and controls did not differ on either BMI or menopausal status at first diagnosis or at reference date. Cases were more likely to have been diagnosed with a localized first breast cancer than controls. Controls were more likely to receive hormonal-based therapy and chemotherapy.
Association Between OC Use and Asynchronous Bilateral Breast Cancer
OC use at any time before the woman's reference date was not associated with risk of asynchronous bilateral breast cancer (relative risk [RR] ϭ 0.88; 95% CI, 0.67 to 1.15) ( Table 2) . OC use before a woman's first breast cancer diagnosis was not significantly associated were at a nonsignificant increased risk. As expected, women who used OCs after diagnosis were younger than those who did not (mean age, 39.3 Ϯ 7.0 v 45.6 Ϯ 6.2 years; P Ͻ .001) and were more likely to be preor perimenopausal compared to nonusers (97.3% v 65.9%; P Ͻ .001), but did not differ from nonusers in terms of mean duration of time at-risk (4.9 Ϯ 5.0 v 4.1 Ϯ 5.0 years). Neither age at first use (Table 2 ) nor age at last use (data not shown) was associated with risk of asynchronous bilateral breast cancer. Years of use before age 30 and before first full-term pregnancy were also not associated with risk (data not shown). We observed no significant differences in the risk estimates for ever-users and never users of OCs by latency, age at onset, BMI, menopausal status, or hormone-receptor status (data not shown).
Association Between PMH Use and Asynchronous Bilateral Breast Cancer
Women who had used PMH before their reference dates did not have an elevated risk of asynchronous bilateral breast cancer (RR ϭ 1.03; 95% CI, 0.79 to 1.36; Table 3 ). We found no evidence to suggest that latency, age at onset, BMI, menopausal status, or hormonereceptor status modified this association (data not shown). Age at first (Table 3 ) and last use (data not shown), PMH formulation, and lifetime duration of use were also not associated with risk.
We did not observe a statistically significant increased risk of asynchronous bilateral breast cancer with ever-use before (RR ϭ 1.21; 95% CI, 0.90 to 1.61) or after (RR ϭ 1.10; 95% CI, 0.67 to 1.77) the woman's first breast cancer diagnosis. The majority of women who took PMH after their diagnoses were postmenopausal (84.1%) or going through the menopause (11.2%). Age at first diagnosis did not differ between women who used PMH after their diagnoses of breast cancer and those who did not (45.4 Ϯ 6.3 v 47.3 Ϯ 5.1 years); however, we observed a statistically significant difference in the time at-risk between users and nonusers (6.4 Ϯ 3.2 v 5.0 Ϯ 3.1 years). When we examined duration of use before and after diagnosis, we found no significant associations. Women who stopped using PMH more than 5 years before first breast cancer (RR ϭ 1.75; 95% CI, 0.95 to 3.21) or after a diagnosis of breast cancer (RR ϭ 1.54; 95% CI, 0.77 to 3.10) were not at a significantly increased risk compared to never users.
DISCUSSION
Results from this large, population-based, case-control study provide little evidence that use of either OC or PMH substantially increases the risk of asynchronous bilateral breast cancer. To our knowledge, ours is the first study to examine OC and PMH effects in terms of duration and age of use, as well as use before and after a diagnosis of breast cancer. Our results showed that OC use after diagnosis was associated with a modest nonsignificant increased risk. Most of the 37 women who used OCs after diagnosis were premenopausal, and their duration of use was short. We found little indication that PMH use before or after a breast cancer diagnosis substantially increased risk of asynchronous bilateral breast cancer. We also found no indication of an increased risk associated with duration of use, age at use, or type of PMH. Women in this study were relatively young at diagnosis; therefore, initiation of PMH use was likely close to menopause and for relief of symptoms. Furthermore, fewer than half of women taking PMH were exclusive EPT users. The Women's Health Initiative study 8 suggests that PMH (particularly, EPT) use may increase the risk of first breast cancer among older women who use PMH long after menopause. We did not observe any evidence that latency, age at onset, BMI, menopausal status or hormone-receptor status modified the associations between OCs or PMH and risk of asynchronous bilateral breast cancer.
Four previously published studies investigating OC use and risk of contralateral breast cancer also found no evidence to support an NOTE: Frequency counts do not necessarily sum to the total number of individuals due to missing data. *P values adjusted for sampling weights. †Time interval between first and second diagnoses for cases and first diagnosis and equivalent date for controls; reference date refers to the date at second breast cancer for cases (bilateral breast cancer) and equivalent date for controls (unilateral breast cancer).
‡Variables used in matching strategy. §Variable used for counter-matching.
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association.
2-5 Two population-based cohort studies showed that risk of second breast cancer was not associated with OCs. 3, 4 A third population-based study among women diagnosed younger than age 45 found no duration of use effect when comparing women with at least 10 years of use and those with less than 10 years of use with never-users. 5 Further, a small hospital-based case-control study showed no association between any use of OCs and risk of contralateral breast cancer.
2 Despite differences in design, all studies, including the present study, suggest that OC use is unlikelyto be associated with a strong increased risk of a subsequent contralateral breast primary. This finding agrees with results from the Women's CARE study of first breast cancer showing no increase in risk with current or former OC use among women aged 35 to 64 years. 6 The CGHFBC, which pooled data from a large number of studies conducted in the 1980s and earlier, found a modest increase in risk of a first breast cancer with current and recent OC use. 7 In the CGHFBC, the majority of OC use was at a higher estrogen dose than is currently used. Abbreviation: RR, rate ratio. *Frequency counts do not necessarily sum to the total number of individuals because of missing data. †Adjusted for the counter-matching sampling. ‡Adjusted for the counter-matching sampling, age at diagnosis of first breast cancer, age at menarche (Ͻ 13, Ն 13 years), menopausal status at reference age (pre-, post-, Ͻ 45 years; post-, Ն 45), number of full-term pregnancies (0, 1, 2, 3, Ն 4), family history of breast cancer in a 1st degree relative (no, yes, adopted, or unknown), histology (lobular, medullary, ductal, or other), stage (localized, regional), chemotherapy (yes, no), hormonal therapy (yes, no), radiation therapy (yes, no).
§In addition, adjusted for use after breast cancer diagnosis.
In addition, adjusted for use before breast cancer diagnosis. ¶Restricted to individuals Ն 25 years old at reference age. #In addition, adjusted for duration of use after breast cancer diagnosis.
Two other population-based studies have investigated the relationship between PMH and risk of subsequent contralateral breast cancer, with results that were similar to ours. Trentham-Dietz 4 found no association for ever or recent use compared with never use. Horn 2 compared ever versus never use for estrogen-only therapy and found no association. The role of PMH has been more widely investigated in first breast cancer. Evidence exists supporting an association of PMH, particularly combined EPT, with a modest increase in breast cancer Abbreviations: PMH, postmenopausal hormones; RR, rate ratio; ET, exclusive estrogen; EPT, exclusive estrogen and progestin; other, other type or progestin only; mix, use of more than one type of PMH. *Frequency counts do not necessarily sum to the total number of individuals due to missing data. †Adjusted for the counter-matching sampling. ‡Adjusted for the counter-matching sampling, age at diagnosis of first breast cancer, age at menarche (Ͻ13, 13ϩ years), menopausal status at reference age (pre-, post-Ͻ45 years, post-45ϩ), number of full-term pregnancies (0, 1, 2, 3, 4ϩ), family history of breast cancer in a first degree relative (no, yes, adopted or unknown), histology (lobular, medullary, ductal or other), stage (localized, regional), chemotherapy (yes, no), hormonal therapy (yes, no), radiation therapy (yes, no).
In addition, adjusted for use before breast cancer diagnosis. ¶Restricted to individuals Ն 45 years old at reference date. #In addition, adjusted for duration of use after breast cancer diagnosis. **In addition, adjusted for duration of use before breast cancer diagnosis.
risk. [9] [10] [11] The CGHFBC found a strong duration response effect, showing that the relative risk of breast cancer increased significantly with each year of PMH use.
10 A meta-analysis focusing on the EPT-specific results from the CGHFBC data confirmed a significant increase in breast cancer risk.
11 Results from the Women's Health Initiative trial 8 and Million Women Study 9 also support these findings. When we examined duration and type of PMH, we observed no increase in risk with years of use or exclusive EPT use. We also did not observe a significant difference in results by BMI. Previous studies of first breast cancer have shown that the PMH-breast cancer association is limitedto slender women. 22 PMH was more strongly associated with hormone-responsive breast cancer, 23 but our data showed no evidence of effect modification by hormone-receptor status of the first breast cancer.
Two clinical trials investigating PMH use in breast cancer survivors showed discordant results. The HABITS trial, with a median follow-up of 2.1 years, found that the risk for breast cancer recurrence was significantly higher among patients who received PMH than among patients receiving no treatment (hazard ratio [HR] ϭ 3.3; 95% CI, 1.5 to 7.4). In contrast, a Swedish randomized trial with a median follow-up of 4.1 years, found no association between risk of recurrence and PMH use (HR ϭ 0.82; 95% CI, 0.35 to 1.95). These studies differ in important ways. The HABITS trial had higher proportions of EPT users and lymph node-positive disease and a lower proportion of Tamoxifen users than the Swedish trial. 13, 14 Observational studies also showed no significant associations between PMH use and tumor recurrence or mortality among breast cancer survivors. [15] [16] [17] Several important limitations should be considered when interpreting our study results. We required that all of our cases and controls be alive at recruitment to obtain a blood sample. To limit this potential survival bias, controls were individually matched to cases on age and year of first breast cancer diagnosis. Further, we restricted study eligibility to women whose breast cancer had not spread beyond regional lymph nodes at first diagnosis. Our study also did not exclude carriers of BRCA1/2 mutations, nor did we analyze the results according to the molecular classification of breast tumors. 24 It is possible that OC/PMH use may be more relevant to certain subtypes of breast cancer, as suggested by studies of first breast cancer in carriers. 25, 26 We were also unable to validate information on use of PMH and OC, or investigate differences in OC formulations. In addition, exposure prevalences were low in some analyses.
Study strengths include the careful matching of cases to controls and the abstraction of medical records to confirm a cancer-free interval for controls. In addition, by limiting initial breast cancer diagnoses to localized and regional disease and specifying a minimum interval of 1 year between the first and second diagnoses of the cases, we limited the potential for misclassification of metastases as second primaries. This study has avoided biases associated with use of highrisk or selected populations by ascertaining cases and controls via multiple population-based cancer registries, which provides broader generalizability of the findings.
These findings have important clinical implications for women with breast cancer. Although current clinical guidelines do not recommend that women with a history of breast cancer use OCs or PMH, results from this large observational study, combined with those from other observational studies and from clinical trials, suggest that use of these exogenous hormone preparations does not increase the risk of second breast primaries.
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